Compare Albertsons Companies Inc (ACI) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs BioNTech SE - ADR — how do they compare? Albertsons Companies Inc trades at $12.05 (market cap $5.95B), while BioNTech SE - ADR trades at $92.57 (market cap $23.31B). The key difference: BioNTech SE - ADR is far larger — about 3.9× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays a 5.55% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ACI | BNTX | |
|---|---|---|
Market Cap | $5.95B | $23.31B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $119.34 |
52-Week Low | $11.03 | $83.89 |
Enterprise Value | $21.35B | $6.60B |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.13, up 1.0% on the day, but remains near multi-year lows after a sharp 22% drop following Q2 2026 earnings miss and lowered guidance. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $80.39B in 2025, but net income margin compressed to 0.08%, reflecting margin pressure. Recent news highlights CEO and CFO stock purchases, AI initiatives like the Safeway ChatGPT plugin, and ongoing shareholder litigation investigations.
The outlook is cautious; ACI presents a deep-value case with low P/S of 0.08, but execution risks and weak profitability trends pose challenges. Analyst consensus is mixed with a $13.20 price target. Key risks include competitive grocery margins, litigation overhangs, and macroeconomic headwinds affecting consumer spending.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
